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Intrahepatic cholestasis of pregnancy (ICP) is a complication of pregnancy resulting in elevation of serum bile acid levels. ICP is
often associated with underlying liver disease, including hepatitis C. Bile acids in relationship to the acute infection of hepatitis C
virus have not yet been delineated in the literature. A 26-year-old gravida 4 para 2103 with dichorionic, diamniotic twin gestation
and history of intravenous drug abuse developed ICP in the setting of acute hepatitis C infection. In addition to clinical symptoms of
pruritus and right upper quadrant pain, she developed severe elevation in bile acids, 239micromol/L, and transaminitis aspartate
aminotransferase 1033U/L, and alanine aminotransferase 448U/L. She received ursodeoxycholic acid and antenatal testing was
performed. Patient delivered vaginally at 33-week gestation following preterm rupture of membranes. Neonates were admitted to
NICU and had uncomplicated neonatal courses. In the setting of ICP with significant transaminitis and severe elevation of bile
acids, consideration of acute viral hepatitis is important, especially considering the worsening opioid epidemic and concurrent
increase in intravenous drug use in the United States. Further study is needed regarding the acute form of HCV infection and its
effect on ICP and associated bile acids.
1. Introduction
Intrahepatic cholestasis of pregnancy (ICP) is a complication
of pregnancy resulting in diffuse pruritus, elevation of serum
bile acid levels, and potential serum transaminitis. ICP is
the most common liver disease diagnosed during pregnancy,
and typically, symptoms manifest in the 2nd or 3rd trimester
of pregnancy. Elevations in bile acids have been shown
to be associated with adverse pregnancy outcomes, most
notably meconium staining of amniotic fluid, fetal asphyxial
events, spontaneous preterm delivery, iatrogenic preterm
delivery, and sudden intrauterine fetal demise [1]. A review
of the literature demonstrates that ICP may be associated
with underlying liver disease, including hepatitis C virus
(HCV) infection. However, much of the literature does not
specifically investigate the acute versus chronic forms ofHCV
infection in relationship to ICP. According to the guidelines
by the American Association for the Study of Liver Diseases
and the Infectious Diseases Society of America, anti-HCV is
the first-line diagnostic test for patients with elevated liver
enzymes or clinical signs of liver disease [2]. A positive
HCV antibody result does not distinguish between acute
and chronic infection of HCV or from a previous infection
that has been cleared spontaneously [2]. Acute hepatitis C
infection can be diagnosed by the presence of HCV RNA
by polymerase chain reaction (PCR) and the absence of
HCV antibodies. HCV RNA is detectable by PCR within
days to eight weeks following exposure, while most patients
seroconvert to HCV antibody positive between two and six
months after exposure [3, 4]. The presence of serum HCV
antibodies may be delayed in those who are immunocom-
promised or pregnant [2]. Of note, approximately 20–50%
of patients will spontaneously clear the HCV infection, with
the majority occurring within 6 months of exposure [5]. The
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purpose of this report is to add to our understanding of the
clinical course of concurrent ICP and the acute form of HCV
infection during pregnancy.
2. Case
A 26-year-old gravida 4 para 2103 with a dichorionic,
diamniotic pregnancy developed intrahepatic cholestasis in
the setting of acute HCV infection. Her obstetrical history
was notable for her three previous pregnancies complicated
by preeclampsia. Her past medical history included opioid
abuse for 7 years including daily intravenous drug use, as well
as tobacco abuse, asthma, and depression. She denied any
personal or family history of liver disease.
At 21 weeks of gestation, the patient was admitted for
voluntary detoxification from intravenous opiate abuse. Dur-
ing this admission, the patient reported significant right back
pain and right upper quadrant abdominal pain. The patient
was found to have transaminitis of unclear etiology, with
respective levels of AST and ALT of 886U/L and 405U/L.
Evaluation at that time included a negative hepatitis panel and
unremarkable right upper quadrant ultrasound.The negative
hepatitis panel demonstrated absence of serum antibodies
for hepatitis A, hepatitis B, and hepatitis C and absence of
hepatitis B surface antigen. During her admission, the patient
was transitioned from detoxification to buprenorphine for
opioid maintenance therapy. Her abdominal pain resolved
spontaneously and the patient was discharged home. At 22
weeks of gestation, the patient presented to a routine prenatal
visit with a complaint of diffuse itching. Ursodeoxycholic
acid 300mg orally three times daily was initiated empirically
for a clinical presentation concerning ICP. A repeat hepatitis
panel was again negative; however HCV RNA PCR was
positive, with viral load of approximately 3 million IU/mL.
Initial level and also highest recorded level of serum bile
acids was 239micromol/L; AST and ALT reached peak
levels of 1033U/L and 448U/L, respectively. The patient was
continued on ursodeoxycholic acid and received standard
antenatal testing. Fetal status remained reassuring through-
out her pregnancy, as evidenced by nonstress tests and serial
ultrasounds. Growth percentiles were 46% and 49% at 27
weeks of gestation, for twin A and twin B, respectively. At
33 weeks of gestation, growth percentiles were 31% and 35%
for twin A and twin B, respectively. Weight discordance
between twins remained at an estimated 3 percent throughout
the duration of the pregnancy. Bile acid levels declined to
12micromol/L and AST and ALT improved to 21U/L and
10U/L, respectively, at 28 weeks of gestation.
At 33 weeks and 6 days of gestation, the patient pre-
sented with preterm premature rupture of membranes and
subsequent pretermdelivery of twins. She had uncomplicated
spontaneous vaginal deliveries: twin A was a 1790 g female
neonate with Apgar scores of 7 and 9, and twin B was a
1800 g male neonate with Apgar scores of 6 and 7. Thin
meconium was noted at the time of delivery of twin A.
Neonates were admitted to the NICU for preterm status and
had uncomplicated neonatal courses. Placental pathology
revealed a dichorionic, diamniotic twin placenta with signifi-
cant findings including dystrophic calcification and increased
syncytial knotting. Specifically, syncytial knots are a marker
of placental maturity and are also strongly associated with
preeclampsia [6].
Maternal postpartum course was complicated by gesta-
tional hypertension, which required oral nifedipine extended
release 30mg twice daily for treatment of elevated blood
pressures. The patient otherwise recovered well in the imme-
diate postpartum period, during which pruritus resolved
spontaneously. Approximately 9 months postpartum, HCV
RNA PCR was negative, indicating spontaneous clearance of
the HCV infection.
3. Discussion
A comprehensive review of the literature was performed
using PubMed with the search terms “intrahepatic cholesta-
sis,” “obstetric cholestasis,” “pregnancy,” and “hepatitis C.”
Our case represents an isolated report of intrahepatic
cholestasis of pregnancy with concurrent acute HCV infec-
tion, notably with a severe elevation of serum bile acid levels.
A strong association exists between ICP and underlying
hepatobiliary dysfunction. In terms of HCV infection and
ICP, a reciprocal relationship may exist. A cohort study by
Marschall et al. suggests that the high prevalence of HCV
infection with ICP may be due to enhanced susceptibility
to HCV in pregnancies affected by ICP, and vice versa [7].
Patients with chronic hepatitis tend to have clinical presen-
tation of ICP at earlier gestational ages as compared to those
patients without HCV [8]. In addition, pregnant women with
concurrent HCV infection have higher hepatitis C viral load
values than patients with HCV infection without ICP. Several
researchers have advocated for routine testing of hepatitis
in pregnancies complicated by ICP [7, 8]. Furthermore, our
case highlights the potential need for reflexive HCV RNA
PCR testing to rule out acute viral infection if initial hepatitis
antibody panels are negative.
The extent to which ICP or hepatitis affects bile acid
levels remains uncertain. Proposedmechanisms of the patho-
physiology of ICP include genetic predisposition with subse-
quent variants of hepatobiliary transport proteins, impaired
turnover of reproductive hormones, and environmental fac-
tors [7]. Furthermore, bile acids in relationship to acute HCV
infection have not yet been elucidated in the literature. HCV
infection may downregulate expression of the ATP-binding
cassette transporter MRP2 found in the liver, resulting in a
relative failure in the transport of various toxins. This failure
combined with high circulating serum estrogen levels during
pregnancy may increase the risk of ICP and may enhance
symptoms of cholestatic pruritus [9].
An increased incidence of ICP has been demonstrated
among twin pregnancies [10]. In our case, the severity of bile
acid elevationmay be confounded bymultiple factors includ-
ing the patient’s multifetal gestation, history of preeclampsia,
the uncertain timeline of her acquisition of the hepatitis C
virus, and the acute nature of the HCV infection. Specifically,
Wikström Shemer et al. have demonstrated an increased
incidence of preeclampsia among pregnancies affected by
ICP, with adjusted odds ratio 2.62 [11]. Additionally, a
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recent retrospective cohort study of 78 patients with ICP
has revealed that severe ICP (total bile acid level greater
than 40micromol/L) is noted as a significant risk factor for
preeclampsia in both singleton and twin pregnancies [12].
Interestingly, patients with bile acid levels less than 20 did
not develop preeclampsia in this study [12]. As seen in our
case, normalization of bile acid levels and liver function tests
typically occurs within one to three weeks of treatment with
ursodeoxycholic acid [12]. Despite normalization of these
laboratory values, the development of preeclampsia remains
a subsequent event later in pregnancy, perhaps suggesting
that the initial elevation in bile acids may act to promote
the development of hypertensive disorders of pregnancy [12].
Further studies are necessary to delineate the causative factors
contributing to bile acids reaching severe levels in ICP.
Many studies have examined bile acid levels in asso-
ciation with adverse pregnancy outcomes. A positive lin-
ear correlation exists between bile acid levels and adverse
fetal outcomes including meconium staining of amniotic
fluid, fetal asphyxial events, spontaneous preterm delivery,
iatrogenic preterm delivery, and sudden intrauterine fetal
demise [1, 13]. Several studies have delineated levels of bile
acids in terms of severity and subsequent fetal complication
rates. A prospective cohort study by Glantz et al. suggested
an additional one to two percent increased risk of adverse
events for each additional micromol/L of bile acid level above
40micromol/L [1]. In 2015, Brouwers et al. conducted a
retrospective cohort study that demonstrated an increased
risk of adverse fetal complications with bile acids greater than
100micromol/L [14]. Additionally, this study noted a positive
correlation among maternal and fetal bile acid levels and
revealed that, for each 10micromol/L increase of bile acids,
there is an increased risk of perinatal death (𝑃 = 0.039),
with an odds ratio of 1.26 when adjusted for gestational
age, maternal age, and birthweight [14]. This is equivalent
to a 10% risk of stillbirth if bile acids are greater than
100micromol/L [14]. Comparably, a 2015 retrospective cohort
study by Kawakita et al. reaffirmed that bile acid levels greater
than 40micromol/L were associated with increased risk of
meconium-stained amniotic fluid (OR 3.55, CI 1.45–8.68),
as well as the association between bile acids greater than
100 𝜇mol/L and an increased risk of stillbirth [13].
While the relationship of bile acid levels and adverse
pregnancy outcomes is clear, the timing for optimal delivery
for patients with ICP has not yet been formally established.
Multiple studies have demonstrated benefit for delivery at 37
weeks of gestation if bile acids are greater than 40micromol/L
[1, 14]. Brouwers et al. proposed late pretermdelivery between
34 and 37 weeks of gestation for pregnancies complicated
by bile acids greater than 100micromol/L in the setting of
ICP [14]. Important to consider is the temporality of bile
acid elevation during pregnancy. As emphasized in our case,
does a rapid onset of bile acid elevation affect rates of fetal
complications?
Furthermore, patients with ICP are at risk of subsequent
development of cirrhosis and other liver, biliary, and pan-
creatic diseases [15]. Specifically considering concomitant
acute HCV infection, postpartum follow-up and further
management are likely to be beneficial for these patients.
4. Conclusions
In the setting of ICP with significant transaminitis and severe
levels of bile acids, consideration of acute viral hepatitis is
important. In particular with the increasing opioid epidemic
and concurrent increase in intravenous drug use in the
United States, the prevalence of acute HCV infection may
be increasing among pregnant women. Reflexive hepatitis C
RNA PCR testing to rule out acute viral infection if initial
hepatitis antibody panels are negative may be warranted in
patients with ICP and concurrent severe elevation in bile
acid levels. Diagnosis of acute HCV infection may help to
distinguish a subset of patients with ICP and severe levels
of bile acids; this may result in alteration of guidelines for
optimal delivery planning. The effect of acute HCV infection
on the setting of ICP in relation to severity of bile acid
elevation and associated adverse pregnancy complications
deserves further study.
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